title: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
abstract: BACKGROUND
  The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC.
  
  
  METHODS
  A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches.
  
  
  CONCLUSIONS
  The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
authors.affiliation: Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium.
authors.forename: R
authors.initials: R
authors.lastname: Salgado
authors.affiliation: Institute of Pathology, Charité -University Hospital, Berlin, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Denkert
authors.affiliation: Perlmutter Cancer Center, New York University Medical School, New York, USA.
authors.forename: S
authors.initials: S
authors.lastname: Demaria
authors.affiliation: Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: N
authors.initials: N
authors.lastname: Sirtaine
authors.affiliation: Institute of Pathology, Charité -University Hospital, Berlin, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Klauschen
authors.affiliation: European Institute of Oncology (IEO) and University of Milan, Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Pruneri
authors.affiliation: Institute of Pathology, Charité -University Hospital, Berlin, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Wienert
authors.affiliation: Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium.
authors.forename: G
authors.initials: G
authors.lastname: Van den Eynden
authors.affiliation: Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA.
authors.forename: F L
authors.initials: FL
authors.lastname: Baehner
authors.affiliation: Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France.
authors.forename: F
authors.initials: F
authors.lastname: Penault-Llorca
authors.affiliation: Division of Haematology/Medical Oncology and.
authors.forename: E A
authors.initials: EA
authors.lastname: Perez
authors.affiliation: Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville.
authors.forename: E A
authors.initials: EA
authors.lastname: Thompson
authors.affiliation: Department of Pathology, The UT M.D. Anderson Cancer Center, Boston.
authors.forename: W F
authors.initials: WF
authors.lastname: Symmans
authors.affiliation: Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston.
authors.forename: A L
authors.initials: AL
authors.lastname: Richardson
authors.affiliation: Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA.
authors.forename: J
authors.initials: J
authors.lastname: Brock
authors.affiliation: Istituto Europeo di Oncologia, Milan, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Criscitiello
authors.affiliation: Genomic Health, Inc., Redwood City, USA.
authors.forename: H
authors.initials: H
authors.lastname: Bailey
authors.affiliation: Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels.
authors.forename: M
authors.initials: M
authors.lastname: Ignatiadis
authors.affiliation: Department of Pathology, University Hospital Leuven, Leuven, Belgium.
authors.forename: G
authors.initials: G
authors.lastname: Floris
authors.affiliation: Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA.
authors.forename: J
authors.initials: J
authors.lastname: Sparano
authors.affiliation: Laboratory Medicine Program, University Health Network, University of Toronto, Toronto.
authors.forename: Z
authors.initials: Z
authors.lastname: Kos
authors.affiliation: Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada.
authors.forename: T
authors.initials: T
authors.lastname: Nielsen
authors.affiliation: Department of Pathology, Yale University School of Medicine, New Haven.
authors.forename: D L
authors.initials: DL
authors.lastname: Rimm
authors.affiliation: Department of Pathology, Stanford University Medical Centre, Stanford.
authors.forename: K H
authors.initials: KH
authors.lastname: Allison
authors.affiliation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Reis-Filho
authors.affiliation: German Breast Group, Neu-Isenburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Loibl
authors.affiliation: Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels.
authors.forename: C
authors.initials: C
authors.lastname: Sotiriou
authors.affiliation: Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Viale
authors.affiliation: Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA.
authors.forename: S
authors.initials: S
authors.lastname: Badve
authors.affiliation: Perlmutter Cancer Center, New York University Medical School, New York, USA.
authors.forename: S
authors.initials: S
authors.lastname: Adams
authors.affiliation: Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Willard-Gallo
authors.affiliation: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia sherene.loi@petermac.org.
authors.forename: S
authors.initials: S
authors.lastname: Loi
mesh_terms: D001943:Breast Neoplasms / Q000276:immunology*; D005260:Female; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating
keywords: breast cancer (BC); clinical validity; prediction; prognosis; tumor-infiltrating lymphocytes (TILs)